Voronoi to Present Early Clinical Data on VRN11 Ahead of Schedule at AACR 2025
2025.02.10
'Phase 1 clinical trial of an oral anticancer drug for EGFR non-small cell lung cancer in patients refractory to or progressed on available standard therapies including existing TKIs; expectations for confirmation of efficacy/safety starting from low doses'
Voronoi will present early clinical trial data on VRN11, the EGFR non-small cell lung cancer targeted therapy it is developing, at the American Association for Cancer Research Annual Meeting (AACR 2025).
Voronoi announced that it will present a poster at the AACR 2025 Annual Meeting, to be held in Chicago, Illinois, U.S., from April 25 to 30 (local time). According to the conference schedule, the abstract will be released on the conference website on March 25.
The company had stated last November that it aimed to present interim results of the Phase 1a clinical trial of VRN11 at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, so curiosity and expectations are growing as to the background of the earlier-than-planned presentation.
VRN11 is a fourth-generation EGFR non-small cell lung cancer targeted therapy that Voronoi is developing in-house. It has efficacy superior to existing drugs against EGFR Del19, L858R, C797S, and atypical mutations, or compound mutations thereof, and a Phase 1a dose-escalation study has been under way in Korea and Taiwan since March 2024 in patients refractory to or progressed on available standard therapies, including existing TKIs.
VRN11 has outstanding efficacy across a range of EGFR non-small cell lung cancers, including not only the EGFR C797S acquired resistance mutation but also common mutations such as EGFR Del19 and L858R and atypical mutations such as EGFR G719X, L861Q, and S768I, and with a blood-brain-barrier penetration rate reaching 100% or more in monkey studies, it is a drug capable of treating patients with brain metastases.
In addition, it has secured excellent safety data in GLP non-clinical toxicity studies, and on this basis an aggressive dose-escalation study (100-100-100-100-50% escalation) is under way.
To pursue aggressive clinical development of VRN11, Voronoi obtained approval from the Ministry of Food and Drug Safety for amendments, through two rounds of clinical protocol changes, that expanded the Phase 1 trial size from 50 to 103 patients and substantially expanded the dose-escalation ratio and targets.
In January of this year, the dose escalation from 10 mg to 160 mg was amended to allow escalation up to 320 mg, and the second amendment allows the dose to be further expanded in 80 mg increments if no dose-limiting toxicity (DLT) appears at 320 mg. These amendments were possible because the safety of VRN11 in humans has been confirmed in the clinical trial to date; according to a Voronoi representative, the company expressed strong confidence in the safety of VRN11, stating that 'escalation to doses of 400 mg or more is expected.'
For targeted anticancer drugs, as long as safety is secured, maintaining high effective drug concentrations in the blood through high-dose administration is essential for improving long-term efficacy outcomes such as PFS and OS.
In addition, the current patient selection criteria for VRN11 include patients with disease progression (PD) confirmed by radiological assessment despite standard treatment regimens including EGFR TKIs, patients whose treatment was discontinued due to toxicity, and patients confirmed to derive no clinical benefit from other standard treatment regimens, so the trial targets 'heavily treated' patients who have gone through multiple treatment options.
As the dose-escalation cohorts proceed sequentially in heavily treated patients, VRN11 aims to accumulate efficacy and safety data and to enroll EGFR Del19/L858R and EGFR atypical mutation naïve patients starting from the Phase 1b trial.
In a similar case, ORIC Pharmaceuticals, a NASDAQ-listed U.S. company conducting a Phase 1 clinical trial of ORIC-114 (VRN07), a targeted therapy for EGFR exon20 insertion mutation non-small cell lung cancer, started a cohort of EGFR TKI naïve patients in its Phase 1b trial in April 2024 based on the therapeutic effect in 'heavily treated' patients, and is currently aiming for a first-line treatment option for EGFR exon20 insertion mutation non-small cell lung cancer.
Voronoi will present early clinical trial data on VRN11, the EGFR non-small cell lung cancer targeted therapy it is developing, at the American Association for Cancer Research Annual Meeting (AACR 2025).
Voronoi announced that it will present a poster at the AACR 2025 Annual Meeting, to be held in Chicago, Illinois, U.S., from April 25 to 30 (local time). According to the conference schedule, the abstract will be released on the conference website on March 25.
The company had stated last November that it aimed to present interim results of the Phase 1a clinical trial of VRN11 at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, so curiosity and expectations are growing as to the background of the earlier-than-planned presentation.
VRN11 is a fourth-generation EGFR non-small cell lung cancer targeted therapy that Voronoi is developing in-house. It has efficacy superior to existing drugs against EGFR Del19, L858R, C797S, and atypical mutations, or compound mutations thereof, and a Phase 1a dose-escalation study has been under way in Korea and Taiwan since March 2024 in patients refractory to or progressed on available standard therapies, including existing TKIs.
VRN11 has outstanding efficacy across a range of EGFR non-small cell lung cancers, including not only the EGFR C797S acquired resistance mutation but also common mutations such as EGFR Del19 and L858R and atypical mutations such as EGFR G719X, L861Q, and S768I, and with a blood-brain-barrier penetration rate reaching 100% or more in monkey studies, it is a drug capable of treating patients with brain metastases.
In addition, it has secured excellent safety data in GLP non-clinical toxicity studies, and on this basis an aggressive dose-escalation study (100-100-100-100-50% escalation) is under way.
To pursue aggressive clinical development of VRN11, Voronoi obtained approval from the Ministry of Food and Drug Safety for amendments, through two rounds of clinical protocol changes, that expanded the Phase 1 trial size from 50 to 103 patients and substantially expanded the dose-escalation ratio and targets.
In January of this year, the dose escalation from 10 mg to 160 mg was amended to allow escalation up to 320 mg, and the second amendment allows the dose to be further expanded in 80 mg increments if no dose-limiting toxicity (DLT) appears at 320 mg. These amendments were possible because the safety of VRN11 in humans has been confirmed in the clinical trial to date; according to a Voronoi representative, the company expressed strong confidence in the safety of VRN11, stating that 'escalation to doses of 400 mg or more is expected.'
For targeted anticancer drugs, as long as safety is secured, maintaining high effective drug concentrations in the blood through high-dose administration is essential for improving long-term efficacy outcomes such as PFS and OS.
In addition, the current patient selection criteria for VRN11 include patients with disease progression (PD) confirmed by radiological assessment despite standard treatment regimens including EGFR TKIs, patients whose treatment was discontinued due to toxicity, and patients confirmed to derive no clinical benefit from other standard treatment regimens, so the trial targets 'heavily treated' patients who have gone through multiple treatment options.
As the dose-escalation cohorts proceed sequentially in heavily treated patients, VRN11 aims to accumulate efficacy and safety data and to enroll EGFR Del19/L858R and EGFR atypical mutation naïve patients starting from the Phase 1b trial.
In a similar case, ORIC Pharmaceuticals, a NASDAQ-listed U.S. company conducting a Phase 1 clinical trial of ORIC-114 (VRN07), a targeted therapy for EGFR exon20 insertion mutation non-small cell lung cancer, started a cohort of EGFR TKI naïve patients in its Phase 1b trial in April 2024 based on the therapeutic effect in 'heavily treated' patients, and is currently aiming for a first-line treatment option for EGFR exon20 insertion mutation non-small cell lung cancer.